AstraZeneca Extends Innate Pharma Collaboration
This announcement contains inside information 23 October 2018 07:00 BST [CBR issued at 06:00 BST] AstraZeneca strengthens and expands oncology developmentand commercialisation collaboration with Innate Pharma Full oncology rights to monalizumab Access to Innate Pharma's anti-CD39 monoclonal antibody,IPH5201, plus four additional immuno-oncology molecules Innate Pharma acquires US and EU rights to commercialise Lumoxiti Purchase of newly-issued 9.8% equity stake in Innate Pharma AstraZeneca, and its global biologics research and development arm MedImmune, today